Avacta Group
Market Cap
UK£329.2m
Last Updated
2021/01/18 20:23 UTC
Data Sources
Company Financials +
Executive Summary
Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. More Details
Rewards
Risk Analysis
Earnings are forecast to decline by an average of 25.2% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Avacta Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AVCT is more volatile than 90% of UK stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: AVCT's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of UK stocks.
Market Performance
7 Day Return
-3.8%
AVCT
6.6%
GB Biotechs
-0.7%
GB Market
1 Year Return
584.9%
AVCT
45.4%
GB Biotechs
-8.5%
GB Market
Return vs Industry: AVCT exceeded the UK Biotechs industry which returned 45.4% over the past year.
Return vs Market: AVCT exceeded the UK Market which returned -8.5% over the past year.
Shareholder returns
| AVCT | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.8% | 6.6% | -0.7% |
| 30 Day | 9.2% | 13.4% | 3.8% |
| 90 Day | -32.8% | 11.0% | 14.6% |
| 1 Year | 584.9%584.9% | 46.1%45.4% | -4.7%-8.5% |
| 3 Year | 88.0%88.0% | 10.1%8.7% | 3.9%-8.8% |
| 5 Year | 0.4%0.4% | 53.7%50.9% | 47.6%14.1% |
Long-Term Price Volatility Vs. Market
How volatile is Avacta Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
What Kind Of Shareholders Hold The Majority In Avacta Group Plc's (LON:AVCT) Shares?1 month ago | Simply Wall St
How Is Avacta Group's (LON:AVCT) CEO Paid Relative To Peers?2 months ago | Simply Wall St
The Avacta Group (LON:AVCT) Share Price Has Soared 458%, Delighting Many ShareholdersValuation
Is Avacta Group undervalued compared to its fair value and its price relative to the market?
3.28x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AVCT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AVCT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AVCT is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: AVCT is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AVCT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AVCT is good value based on its PB Ratio (3.3x) compared to the GB Biotechs industry average (7.3x).
Next Steps
Future Growth
How is Avacta Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-25.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AVCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AVCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AVCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AVCT's revenue (43.3% per year) is forecast to grow faster than the UK market (6.5% per year).
High Growth Revenue: AVCT's revenue (43.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AVCT's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Avacta Group performed over the past 5 years?
-20.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AVCT is currently unprofitable.
Growing Profit Margin: AVCT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AVCT is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accelerating Growth: Unable to compare AVCT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).
Return on Equity
High ROE: AVCT has a negative Return on Equity (-17.2%), as it is currently unprofitable.
Next Steps
Financial Health
How is Avacta Group's financial position?
Financial Position Analysis
Short Term Liabilities: AVCT's short term assets (£60.4M) exceed its short term liabilities (£3.1M).
Long Term Liabilities: AVCT's short term assets (£60.4M) exceed its long term liabilities (£568.0K).
Debt to Equity History and Analysis
Debt Level: AVCT is debt free.
Reducing Debt: AVCT has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVCT has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AVCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 10.7% each year
Next Steps
Dividend
What is Avacta Group current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AVCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AVCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AVCT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AVCT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AVCT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
5.0yrs
Average management tenure
CEO
Alastair Smith
16yrs
Tenure
UK£328,000
Compensation
Prof. Alastair Smith co-founded Avacta Group Plc in January 2004 and has been its Chief Executive Officer since 2005. Prof. Smith serves as the Chief Executive Officer of Avacta Ltd. He is a Professor of M...
CEO Compensation Analysis
Compensation vs Market: Alastair's total compensation ($USD445.25K) is below average for companies of similar size in the UK market ($USD823.73K).
Compensation vs Earnings: Alastair's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 16yrs | UK£328.00k | 0.17% £ 569.0k | |
| CFO, Company Secretary & Executive Director | 5yrs | UK£245.00k | 0.0033% £ 10.8k | |
| Operations Director | 1yr | no data | no data | |
| Chief Technology Officer | 5yrs | no data | no data | |
| Chief Scientific Officer | 8yrs | no data | no data | |
| Marketing & Communications Manager | no data | no data | no data | |
| Chief Development Officer of Avacta Life Sciences | 0.42yr | no data | no data |
5.0yrs
Average Tenure
Experienced Management: AVCT's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 16yrs | UK£328.00k | 0.17% £ 569.0k | |
| CFO, Company Secretary & Executive Director | 5yrs | UK£245.00k | 0.0033% £ 10.8k | |
| Independent Non-Executive Director | 7.42yrs | UK£46.00k | 0.043% £ 141.8k | |
| Member of Scientific Advisory Board | 4.83yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.83yrs | no data | no data | |
| Non-Executive Chairman | 2.58yrs | UK£120.00k | 0.061% £ 202.4k | |
| Member of Scientific Advisory Board | 4.17yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.83yrs | no data | no data | |
| Chairman of Scientific Advisory Board & Senior Independent Director | 4.83yrs | UK£44.00k | no data | |
| Non-Executive Director | 0.92yr | no data | no data |
4.8yrs
Average Tenure
54yo
Average Age
Experienced Board: AVCT's board of directors are considered experienced (4.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AVCT insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.4%.
Top Shareholders
Company Information
Avacta Group Plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Avacta Group Plc
- Ticker: AVCT
- Exchange: AIM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£329.235m
- Shares outstanding: 249.42m
- Website: https://www.avacta.com
Number of Employees
Location
- Avacta Group Plc
- Thorp Arch Estate
- Unit 20
- Wetherby
- West Yorkshire
- LS23 7FA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AVCT | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Aug 2006 |
| AVCT.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Aug 2006 |
| RTQ1 | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Aug 2006 |
Biography
Avacta Group Plc offers reagents and therapeutics based on Affimer technology for diagnostic and research applications in the United Kingdom, North America, Asia, and rest of Europe. It operates in Diagnos...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/18 20:23 |
| End of Day Share Price | 2021/01/18 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.